Cancer screening with cell-free DNA in Li-Fraumeni Syndrome: Feasibility study prior to national trial
About This Grant
Project Summary Individuals with Li-Fraumeni Syndrome (LFS) are at high risk of developing cancer, with 80-90% lifelong chance of malignancy. Screening protocols – leaning heavily on imaging surveillance – have been shown to improve survival through early cancer detection. However, these protocols are imperfect, with high false positive rates and the inability to detect all cancers prior to onset of symptoms. Additionally, screening is associated with significant anxiety and distress in people with LFS and their families. Improved methods of cancer screening are crucial for this at-risk population, as earlier cancer detection is tied to improved survival, improved treatment-related morbidity, and decreased secondary malignancy risk if radiation therapy can be avoided. Early cancer detection through testing of circulating tumor DNA (ctDNA) holds great promise for individuals with LFS. The EDISYN (Early Detection in SYNdromic Cancers) Consortium is planning a randomized controlled trial (RCT) evaluating the efficacy of adding ctDNA screening to standard of care screening protocols in detecting cancer earlier in individuals with LFS. This trial is being planned in collaboration with the ECOG-ACRIN Cancer Research Group, the CHARM (cell-free DNA in Hereditary and High-Risk Malignancies) Consortium, and patient advocacy organizations. We plan to recruit over 1,000 pediatric and adult participants with LFS at many centers across the United States, and thus pilot and feasibility data are required prior to study initiation. In this U34 proposal, the EDISYN Consortium will generate pilot and feasibility data that will ensure success of the planned RCT assessing the addition of ctDNA testing to cancer screening in LFS. In Aim 1, we will pilot ctDNA cancer screening using a test developed and validated by the CHARM Consortium, with the hypothesis that we will provide clinically actionable results within 4 weeks to all participants, and that subjects with a positive result will then undergo follow up testing to evaluate for malignancy with limited cost and barriers to care. In Aim 2, we will pilot a battery of patient-reported outcome measures (PROM) to obtain baseline data and assess acceptability of these measures for the future trial. Our hypothesis is that PROM will describe a range of logistical and psychological barriers that will be actionable in planning the future RCT. We expect that the completion of the above aims will inform the design of an impactful RCT hypothesizing that ctDNA screening will improve time to cancer detection in individuals with LFS. Furthermore, these pilot data are crucial to achieving the primary outcome of the planned RCT or - should pilot data reveal lack of feasibility of the planned RCT - modifying the primary outcome prior to trial initiation.
Grant Summary
Cancer screening with cell-free DNA in Li-Fraumeni Syndrome: Feasibility study prior to national trial is a NCI - National Cancer Institute grant providing up to $427K for university, nonprofit, healthcare org. Applications are due 2029-06-30 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $427K
2029-06-30
- 1Confirm your organization is eligible for Cancer screening with cell-free DNA in Li-Fraumeni Syndrome: Feasibility study prior to national trial from NCI - National Cancer Institute, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NCI - National Cancer Institute before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NCI - National Cancer Institute's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Cancer screening with cell-free DNA in Li-Fraumeni Syndrome: Feasibility study prior to national trial: Frequently Asked Questions
Who is eligible for the Cancer screening with cell-free DNA in Li-Fraumeni Syndrome: Feasibility study prior to national trial?
Cancer screening with cell-free DNA in Li-Fraumeni Syndrome: Feasibility study prior to national trial is offered by NCI - National Cancer Institute and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Cancer screening with cell-free DNA in Li-Fraumeni Syndrome: Feasibility study prior to national trial provide?
Cancer screening with cell-free DNA in Li-Fraumeni Syndrome: Feasibility study prior to national trial provides up to $427K per award from NCI - National Cancer Institute. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Cancer screening with cell-free DNA in Li-Fraumeni Syndrome: Feasibility study prior to national trial deadline?
Applications for Cancer screening with cell-free DNA in Li-Fraumeni Syndrome: Feasibility study prior to national trial are due 2029-06-30 (open). Because deadlines can change, verify the date with the funder, NCI - National Cancer Institute, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Cancer screening with cell-free DNA in Li-Fraumeni Syndrome: Feasibility study prior to national trial?
To apply for Cancer screening with cell-free DNA in Li-Fraumeni Syndrome: Feasibility study prior to national trial, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NCI - National Cancer Institute.